Lymphoma Treatment Market
Number of pages: 100 | Report Format: PDF | Published date: May 02, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
|
Report Attribute |
Details |
|
Market Size Value in 2022 |
US$ 9.76 billion |
|
Revenue Forecast in 2031 |
US$ 21.02 billion |
|
CAGR |
8.9% |
|
Base Year for Estimation |
2022 |
|
Forecast Period |
2023 to 2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Type, Therapy type, Distribution Channel, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global lymphoma treatment market was valued at US$ 9.76 billion in 2022 and is expected to register a revenue CAGR of 8.9% to reach US$ 21.02 billion by 2031.
Lymphoma Treatment Market Fundamentals
Lymphoma is a form of cancer that starts in the immune system's infection-fighting cells, known as lymphocytes. These cells can be found in the lymph nodes, spleen, thymus, bone marrow, and other organs. Lymphocytes alter and develop uncontrollably in lymphoma patients. Some people are more vulnerable to radiation and certain types of chemicals. Benzene and several agricultural pesticides have been implicated; persons exposed at work, who are at the greatest risk, should follow occupational health recommendations to reduce exposure. Exposure to viruses such as the Epstein-Barr virus or HIV can potentially raise the risk of lymphoma in patients whose immune systems are impaired.
Swelling is most common in the neck, groin, abdomen, and armpits. The swellings are frequently painless. If the swollen glands strain on organs, bones, or other tissues, they might become uncomfortable. Some people mistake lymphoma for back pain. The swelling in lymphoma does not go away. If an infection causes the swelling, pain is more likely to accompany it. Overall, a man's lifetime risk of developing NHL is around 1 in 43, while a woman's risk is about 1 in 53. However, a variety of risk factors can influence each individual's risk. Non-Hodgins’ lymphoma (NHL) can happen at any age. It is one of the most frequent malignancies among children, adolescents, and young people. Despite this, the risk of getting NHL increases with age, and more than half of patients are 65 or older when diagnosed. Since 2015, NHL incidence rates have decreased by roughly 1% yearly. And the death rate fell by 2% per year from 2011 to 2020. However, In the United States, a projected 77,200 new cases of NHL were reported in 2020, accounting for 4.3% of all cancer diagnoses (the eighth most prevalent cancer diagnosis). The most recent recorded incidence was 18.6/100,000 in 2017, representing a 168% rise from the first reported incidence of 11.1/100,000 in 1975. NHL was responsible for an estimated 248,700 global fatalities in 2018, accounting for 2.6% of all oncological mortality. Men had a 0.33% cumulative lifetime risk of NHL mortality, whereas women had a 0.21% risk. Mortality rates in high and low/medium HDI countries were 3.2/100,000 for males and 2.0/100,000 and 1.9/100,000 for women, respectively.
[563214]
Lymphoma Treatment Market Dynamics
The increased prevalence of non-Hodgkin lymphoma globally is one of the primary reasons driving market expansion. Furthermore, the growing geriatric population, which is more susceptible to such ailments, is propelling the market growth. Technological advancements, such as developing novel immune checkpoint inhibitors, which prevent proteins from binding together and increase the strength of T-cell responses against cancer cells, also contribute to market growth.
There is a growing R&D pull to develop novel drugs for treating a wide spectrum of lymphomas, including non-Hodgkin lymphomas. According to the American Cancer Society, an estimated 77,240 people will be diagnosed with non-Hodgkin lymphoma in 2020. This estimate considers people of all ages, including adults and children. Despite this, a wide spectrum of lymphomas, including Burkitt's lymphoma, are considered fairly treatable if diagnosed early. Positive treatment rates are likely to propel worldwide market expansion further. Better illness diagnosis is expected to lead to higher usage of treatments, propelling the global market forward.
Furthermore, product launches and approvals are driving the market's growth. For example, Oncodesign, a French business, announced a collaboration with Covalab, CheMatech, and ABX-CRO in June 2021 to introduce the DRIVE-MRT (Molecular irradiation) solution, which may provide a complete drug development process specialized in targeted systemic irradiation. Such new launches will increase the number of innovative items on the market, increasing market growth.
The lower lymphoma treatment rates in emerging nations are key limiting factors constraining expansion. This is due to the high expense of treatments. As a result, only a few people receive this treatment, and many of these patients cannot afford treatments like immunotherapies. The cost of such goods is frequently inaccessible and unaffordable to impoverished patients in these nations, as is the lack of adequate payment arrangements for treating certain disorders.
Lymphoma Treatment Market Ecosystem
The global lymphoma treatment market is analyzed from the following perspectives: by type, therapy type, distribution channel, and region.
Lymphoma Treatment Market by Type
Based on the types, the global lymphoma treatment market is segmented into non-Hodgkin lymphoma and Hodgkin lymphoma.
Non-Hodgkin lymphoma maintained the largest revenue share during the forecast period because of the availability of blockbuster treatments such as Revlimid, Rituxan, and Imbruvica, some of the most revenue-generating cancer drugs.
Due to the label extension of current medications and the emergence of novel treatments for relapsed or refractory HL, Hodgkin lymphoma is predicted to grow the fastest throughout the projection period. One of the factors projected to promote growth is the availability of a robust product pipeline and the planned commercialization of these products.
Lymphoma Treatment Market by Therapy Type
[45789123]
Based on the therapy types, the global lymphoma treatment market is segmented into chemotherapy, targeted therapy, and immunotherapy.
The immunotherapy segment will likely dominate the global market during the forecast period. Immunotherapies, such as Yescarta by Kite Pharma, Inc. (Gilead Sciences, Inc.), are a global market leader in this therapeutic segment. Because of the wide variety of product outlook for lymphoma treatment, the targeted therapy segment accounts for the second biggest segment of the global market. Other factors that will contribute to the growth of this segment during the forecast period include the accuracy of these therapies in cancer targeting. Chemotherapy is an important therapeutic choice since it is one of the treatment mainstays.
Lymphoma Treatment Market by Distribution Channel
Based on the distribution channels, the global lymphoma treatment market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies.
Hospital pharmacies dominate because these drugs are usually consumed in hospitals and are mostly provided in hospital pharmacies. This enables adequate therapy while under the supervision of healthcare specialists. Because the treatment is mostly provided to hospitalized patients, retail pharmacies are expected to have a lower CAGR. Furthermore, because lymphoma patients require chronic care medications on a regular basis, online pharmacies are expected to grow at a healthy CAGR.
Lymphoma Treatment Market by Region
Based on the regions, the global lymphoma treatment market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
North America held a dominant position in the market in 2022. Some factors that have contributed to the region's dominance in the global market include a higher prevalence of lymphoma, greater awareness among the patient population for lymphoma treatment, a higher rate of adoption of advanced lymphoma therapeutic drugs, and the region's higher healthcare expenditure. Furthermore, constant R&D by key market players in the form of clinical trials for new drug candidates for lymphoma treatment has boosted the region's market. Europe is predicted to be the second most dominating market over the projection period, and one of the reasons for the region's significant share is the region's large population.
During the forecast period, the Asia-Pacific market is expected to have the highest CAGR of any region of the global market. The key reasons for the region's rapid growth include the approval of key drugs such as Kymriah (tisagenlecleucel) in Japan for lymphoma treatment, the region's untapped market potential, and the presence of a large potential patient population in need of treatment, all of which are expected to drive market growth during the forecast period.
Lymphoma Treatment Market Competitive Landscape
Some of the prominent market players in the lymphoma treatment market include,
Lymphoma Treatment Market Strategic Developments
Lymphoma is a form of cancer that starts in the immune system's infection-fighting cells, known as lymphocytes. These cells can be found in the lymph nodes, spleen, thymus, bone marrow, and other organs.
North America is dominating the global lymphoma treatment market.
Key companies are pursuing various strategies, such as mergers and acquisitions, to enhance their market share. Furthermore, players collaborate to launch their products in different regions to strengthen their market position.
The immunotherapy segment is dominating the lymphoma treatment market
The factors such as the high cost of available treatments and less awareness among people are restricting the market.
*Insights on financial performance are subject to the availability of information in the public domain